Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
25 Apr 24
8-K
Dexcom Reports First Quarter 2024 Financial Results
25 Apr 24
ARS
2023 FY
Annual report to shareholders
22 Apr 24
DEF 14A
Definitive proxy
22 Apr 24
8-K
Entry into a Material Definitive Agreement
15 Feb 24
10-K
2023 FY
Annual report
8 Feb 24
8-K
Dexcom Reports Fourth Quarter and Fiscal Year 2023 Financial Results
8 Feb 24
8-K
Dexcom Reports Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2023 and Initial 2024 Outlook
8 Jan 24
8-K
Other Events
2 Nov 23
10-Q
2023 Q3
Quarterly report
26 Oct 23
8-K
Dexcom Reports Third Quarter 2023 Financial Results, Raises 2023 Revenue and Margin Guidance, and Announces $500 Million Share Repurchase Program
26 Oct 23
8-K
Other Events
26 Oct 23
8-K
Departure of Directors or Certain Officers
28 Aug 23
10-Q
2023 Q2
Quarterly report
27 Jul 23
8-K
Dexcom Reports Second Quarter 2023 Financial Results
27 Jul 23
8-K
Dexcom Updates Long-Range Financial Targets
23 Jun 23
SD
Conflict minerals disclosure
31 May 23
8-K
Departure of Directors or Certain Officers
19 May 23
8-K
Entry into a Material Definitive Agreement
5 May 23
8-K
Dexcom Prices Upsized Offering of $1.1 Billion of 0.375% Convertible Senior Notes Due 2028
3 May 23
8-K
Dexcom Announces Proposed Offering of $1.0 Billion of Convertible Senior Notes
2 May 23
10-Q
2023 Q1
Quarterly report
27 Apr 23
8-K
Dexcom Reports First Quarter 2023 Financial Results
27 Apr 23
ARS
2022 FY
Annual report to shareholders
6 Apr 23
DEFA14A
Additional proxy soliciting materials
6 Apr 23
DEF 14A
Definitive proxy
6 Apr 23
10-K
2022 FY
Annual report
9 Feb 23
8-K
Dexcom Reports Fourth Quarter and Fiscal Year 2022 Financial Results
9 Feb 23
8-K
Dexcom Reports Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2022 and Initial 2023 Outlook
9 Jan 23
10-Q
2022 Q3
Quarterly report
27 Oct 22
8-K
Dexcom Reports Third Quarter 2022 Financial Results
27 Oct 22
8-K
Departure of Directors or Certain Officers
31 Aug 22
8-K
Other Events
5 Aug 22
10-Q
2022 Q2
Quarterly report
28 Jul 22
8-K
Other Events
28 Jul 22
8-K
Dexcom Reports Second Quarter 2022 Financial Results
28 Jul 22
8-K
Departure of Directors or Certain Officers
8 Jul 22
8-K
Amendments to Articles of Incorporation or Bylaws
10 Jun 22
SD
Conflict minerals disclosure
31 May 22
8-K
Submission of Matters to a Vote of Security Holders
20 May 22
Latest ownership filings
4
Michael Jon Brown
2 May 24
144
Notice of proposed sale of securities
30 Apr 24
144
Notice of proposed sale of securities
23 Apr 24
4
Matthew Vincent Dolan
16 Apr 24
144
Notice of proposed sale of securities
15 Apr 24
4
KEVIN R SAYER
10 Apr 24
144
Notice of proposed sale of securities
8 Apr 24
144
Notice of proposed sale of securities
1 Apr 24
4
Michael Jon Brown
29 Mar 24
144
Notice of proposed sale of securities
28 Mar 24
4
Sadie Stern
26 Mar 24
144
Notice of proposed sale of securities
25 Mar 24
144
Notice of proposed sale of securities
25 Mar 24
144
Notice of proposed sale of securities
25 Mar 24
144
Notice of proposed sale of securities
22 Mar 24
4
Matthew Vincent Dolan
19 Mar 24
144
Notice of proposed sale of securities
15 Mar 24
144
Notice of proposed sale of securities
15 Mar 24
4
Jereme M Sylvain
14 Mar 24
4
Sadie Stern
14 Mar 24
4
KEVIN R SAYER
14 Mar 24
4
Jacob Steven Leach
14 Mar 24
4
Teri L Lawver
14 Mar 24
4
Matthew Vincent Dolan
14 Mar 24
4
Michael Jon Brown
14 Mar 24
144
Notice of proposed sale of securities
12 Mar 24
144
Notice of proposed sale of securities
12 Mar 24
4
Jereme M Sylvain
11 Mar 24
4
Sadie Stern
11 Mar 24
4
KEVIN R SAYER
11 Mar 24
4
Jacob Steven Leach
11 Mar 24
4
Teri L Lawver
11 Mar 24
4
Matthew Vincent Dolan
11 Mar 24
4
Michael Jon Brown
11 Mar 24
144
Notice of proposed sale of securities
7 Mar 24
144
Notice of proposed sale of securities
6 Mar 24
144
Notice of proposed sale of securities
4 Mar 24
144
Notice of proposed sale of securities
26 Feb 24
4
Jereme M Sylvain
21 Feb 24
144
Notice of proposed sale of securities
20 Feb 24